Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension

Angiogenesis

Volumn 16, Issue 2, 2013, Pages 289-295

  Kruzliak, Peter ^a,b   Kovacova, Gabriela ^c   Pechanova, Olga ^a  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^c UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

Author keywords

Angiogenesis; Anti angiogenic therapy; Cell proliferation; Nitric oxide donors; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CISPLATIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ISOSORBIDE DINITRATE; MOLSIDOMINE; NAVELBINE; SORAFENIB; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; COLORECTAL CANCER; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TREATMENT OUTCOME;

AGED; ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NITRIC OXIDE DONORS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84879507881     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-012-9327-4     Document Type: Review

References (47)

1. Carmeliet P (2000) Mechanisms of angiogenesis and arteriogenesis. Nat Med 6:389-395 (Pubitemid 30208155)
2. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nat Med 1:27-31
3. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29(6 Suppl 16):15-18
4. Klagsbrun M, Moses MA (1999) Molecular angiogenesis. Chem Biol 6:R217-R224 (Pubitemid 29380763)
5. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
6. Verheul HM, Pinedo HM (2007) Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7(6):475-485 (Pubitemid 46809172)
7. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581-611 (Pubitemid 39099316)
8. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669-676 (Pubitemid 36749215)
9. Hood JD, Meininger CJ, Ziche M, Granger HJ (1998) VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 274:H1054-H1058
10. Birk DM, Barbato J, Mureebe L, Chaer RA (2008) Current insights on the biology and clinical aspects of VEGF regulation. Vasc Endovascular Surg 42:517-530
11. Ebos JM, Bocci G, Man S, Thorpe PE, Hicklin DJ, Zhou D, Jia X, Kerbel RS (2004) A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res 2:315-326 (Pubitemid 39025294)
12. Zachary I (2003) VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans 31:1171-1177 (Pubitemid 38030933)
13. Sane DC, Anton L, Brosnihan KB (2004) Angiogenic growth factors and hypertension. Angiogenesis 7:193-201
14. Gelinas DS, Bernatchez PN, Rollin S, Bazan NG, Sirois MG (2002) Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: role of PI3K, PKC and PLC pathways. Br J Pharmacol 137:1021-1030 (Pubitemid 35440742)
15. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N, Nagy A, Roos KP, Iruela-Arispe ML (2007) Autocrine VEGF signaling is required for vascular homeostasis. Cell 130:691-703 (Pubitemid 47268059)
16. Liu MH, Jin HK, Floten HS, Yang Q, Yim AP, Furnary A, Zioncheck TF, Bunting S, He GW (2001) Vascular endothelial growth factor mediated endothelium-dependent relaxation is blunted in spontaneously hypertensive rats. J Pharmacol Exp Ther 296:473-477 (Pubitemid 32112475)
17. Laham RJ, Li J, Tofukuji M, Post M, Simons M, Sellke FW (2003) Spatial heterogeneity in VEGF-induced vasodilation: VEGF dilates microvessels but not epicardial and systemic arteries and veins. Ann Vasc Surg 17:245-252 (Pubitemid 36687572)
18. Wei W, Jin H, Chen ZW, Zioncheck TF, Yim AP, He GW (2004) Vascular endothelial growth factor-induced nitric oxide- and PGI2-dependent relaxation in human internal mammary arteries: a comparative study with KDR and Flt-1 selective mutants. J Cardiovasc Pharmacol 44:615-621 (Pubitemid 39441704)
19. Li B, Ogasawara AK, Yang R, Wei W, He GW, Zioncheck TF, Bunting S, de Vos AM, Jin H (2002) KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension 39:1095-1100 (Pubitemid 34620130)
20. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342 (Pubitemid 38702844)
21. Hurwitz H (2006) Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 33:S26-S34
22. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550 (Pubitemid 44917502)
23. Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96:1788-1795 (Pubitemid 46912024)
24. Hiles JJ, Kolesar JM (2008) Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. Am J Health Syst Pharm 65:123-131
25. Board RE, Thistlethwaite FC, Hawkins RE (2007) Anti-angiogenic therapy in the treatment of advanced renal cell cancer. Cancer Treat Rev 33:1-8 (Pubitemid 46132000)
26. Dhaun N, Webb DJ (2010) Receptor tyrosine kinase inhibition, hypertension, and proteinuria: is endothelin the smoking gun? Hypertension 56(4):575-577
27. Aparicio-Gallego G, Afonso-Afonso FJ, Leon-Mateos L, Firvida-Perez JL, Vazquez-Estevez S, Lazaro-Quintela M, Ramos-Vázquez M, Fernández-Calvo O, Campos-Balea B, Antón-Aparicio LM (2011) Molecular basis of hypertension side effects induced by sunitinib. Anticancer Drugs 22(1):1-8
28. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434 (Pubitemid 36910021)
29. Maki RG, Fletcher JA, Heinrich MC, Morgan JA, George S, Desai J et al (2005) Results from a continuation trial of SU11248 in patients with imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 23:9011
30. Chu TF, Rupnick MA, Kerkela R et al (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011-2019 (Pubitemid 350236338)
31. Azizi M, Chedid A, Oudard S (2008) Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 358:95-97
32. Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329-1338 (Pubitemid 44528723)
33. Azad NS, Posadas EM, Kwitkowski VE et al (2008) Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 26:3709-3714
34. Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S, Fischer P, Ronnen E, Ishill N, Patil S, Motzer RJ (2009) Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 27:1432-1439
35. Govindarajan R, Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI (2006) Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol 24:e48
36. Pouessel D, Culine S (2008) High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 53:376-381 (Pubitemid 350296582)
37. Robinson ES, Khankin EV, Choueiri TK, Dhawan MS, Rogers MJ, Karumanchi SA, Humphreys BD (2010) Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor - signaling inhibitors. Hypertension 56:1131-1136
38. Wu HM, Yuan Y, Zawieja DC, Tinsley J, Granger HJ (1999) Role of phospholipase C protein kinase C and calcium in VEGF-induced venular hyperpermeability. Am J Physiol 276:H535-H542
39. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS, Takagi H, Newsome WP, Jirousek MR, King GL (1996) Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C its isoforms and endothelial cell growth. J Clin Invest 98:2018-2026 (Pubitemid 26376289)
40. Hovens MMC, Steeghs N, Gelderblom H, Op 't Roodt J, Matthys A, Christensen O, Rabelink AJ (2006) VEGFR2 blockade in patients with solid tumors: mechanism of hypertension and effects on vascular function. Vascul Pharmacol 45:e42-e43
41. Chowdhury SJ, Harper PG (2006) Hypertension and targeted therapy. Part 1: Bevacizumab. Targ Oncol 1:104-108 (Pubitemid 44072415)
42. Mourad JJ, Des Guetz G, Debbabi H, Levy BI (2008) Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 19:927-934 (Pubitemid 351627309)
43. Steeghs N, Gelderblom H, Roodt JO, Christensen O, Rajagopalan P, Hovens M, Putter H, Rabelink TJ, de Koning E (2008) Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res 14:3470-3476
44. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, O'Dwyer PJ (2006) Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 24:1363-1369 (Pubitemid 46621999)
45. Chen HX, Cleck JN (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6:465-477
46. Babal P, Pechanova O, Bernatova I, Stvrtina S (1997) Chronic inhibition of NO synthesis produces myocardial fibrosis and arterial media hyperplasia. Histol Histopathol 12:623-629 (Pubitemid 27314692)
47. Hamad AM, Knox AJ (2001) Mechanisms mediating the antiproliferative effects of nitric oxide in cultured human airway smooth muscle cells. FEBS Lett 506(2):91-96 (Pubitemid 32925206) Structural, Engineering and Medical Applications